Novartis and Microsoft have inked a five-year deal to use artificial intelligence to design molecules, personalize medication dosing, and optimize the manufacturing of CAR-T cancer therapy, the two companies announced Tuesday.

The partnership, whose financial terms were not disclosed, marks the latest and one of the more high-profile signs of the inroads that tech is making into drug development. It promises benefits for both sides: Novartis (NVS) will get Microsoft’s help in mining data in search of insights that could help it save and make money, while Microsoft will get a chance to refine its own software for use in the life sciences.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy